---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-009345"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:17:25.271515+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Alzamend Neuro furnishes updated investor presentation for May 2024; no specific new disclosures provided

## Summary
- Filed under Item 7.01 as a Regulation FD disclosure; presentation furnished as Exhibit 99.1.
- Presentation covers therapeutic drugs for Alzheimer's and other neurodegenerative/psychiatric disorders.
- No financial data, clinical trial results, or milestones explicitly stated in the filing's exhibit text.
- Company uses the presentation in meetings with investors, stockholders, and analysts.
- Filing emphasizes forward-looking statements and risks; no material operational changes announced.

## SEC filing metadata
- accession: 0001214659-24-009345
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924009345/0001214659-24-009345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924009345/g5152428k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-009345
- JSON: https://secwatch.observer/filing/0001214659-24-009345.json
- Plain text: https://secwatch.observer/filing/0001214659-24-009345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.